Maureen P. Briscoe

1.1k total citations
25 papers, 882 citations indexed

About

Maureen P. Briscoe is a scholar working on Immunology and Allergy, Physiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Maureen P. Briscoe has authored 25 papers receiving a total of 882 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Immunology and Allergy, 23 papers in Physiology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Maureen P. Briscoe's work include Allergic Rhinitis and Sensitization (24 papers), Asthma and respiratory diseases (23 papers) and Respiratory and Cough-Related Research (7 papers). Maureen P. Briscoe is often cited by papers focused on Allergic Rhinitis and Sensitization (24 papers), Asthma and respiratory diseases (23 papers) and Respiratory and Cough-Related Research (7 papers). Maureen P. Briscoe collaborates with scholars based in Canada, United States and Austria. Maureen P. Briscoe's co-authors include James H. Day, Elizabeth Rafeiro, Anne K. Ellis, Michael D. Widlitz, David L. Buckeridge, Douglass Chapman, P Gervais, Jolene Mason, Eva Pettersson and Anders Åkerlund and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, International Journal of Sports Medicine and Annals of Allergy Asthma & Immunology.

In The Last Decade

Maureen P. Briscoe

25 papers receiving 806 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maureen P. Briscoe Canada 18 793 726 243 208 143 25 882
B. Hauswald Germany 12 246 0.3× 168 0.2× 97 0.4× 142 0.7× 24 0.2× 27 376
Markku Simola Finland 12 226 0.3× 214 0.3× 32 0.1× 125 0.6× 51 0.4× 16 462
Bo Sundin Sweden 9 464 0.6× 388 0.5× 220 0.9× 14 0.1× 110 0.8× 13 654
L Businco Italy 12 140 0.2× 143 0.2× 62 0.3× 21 0.1× 41 0.3× 38 305
Mariana Couto Portugal 12 64 0.1× 244 0.3× 20 0.1× 19 0.1× 199 1.4× 39 414
Max Jessen Sweden 11 151 0.2× 255 0.4× 16 0.1× 92 0.4× 69 0.5× 20 472
Murat Kar Türkiye 9 81 0.1× 97 0.1× 74 0.3× 15 0.1× 37 0.3× 23 258
Anat Galor United States 12 119 0.2× 106 0.1× 92 0.4× 74 0.4× 8 0.1× 17 470
J. M. Henriksen Denmark 9 121 0.2× 355 0.5× 13 0.1× 15 0.1× 278 1.9× 11 412
Silvia Centellas Spain 9 121 0.2× 100 0.1× 6 0.0× 126 0.6× 80 0.6× 9 373

Countries citing papers authored by Maureen P. Briscoe

Since Specialization
Citations

This map shows the geographic impact of Maureen P. Briscoe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maureen P. Briscoe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maureen P. Briscoe more than expected).

Fields of papers citing papers by Maureen P. Briscoe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maureen P. Briscoe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maureen P. Briscoe. The network helps show where Maureen P. Briscoe may publish in the future.

Co-authorship network of co-authors of Maureen P. Briscoe

This figure shows the co-authorship network connecting the top 25 collaborators of Maureen P. Briscoe. A scholar is included among the top collaborators of Maureen P. Briscoe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maureen P. Briscoe. Maureen P. Briscoe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Day, James H., et al.. (2009). Efficacy of loratadine-montelukast on nasal congestion in patients with seasonal allergic rhinitis in an environmental exposure unit. Annals of Allergy Asthma & Immunology. 102(4). 328–338. 15 indexed citations
2.
Day, James H., et al.. (2009). Onset of action of loratadine/montelukast in seasonal allergic rhinitis subjects exposed to ragweed pollen in the Environmental Exposure Unit. Allergy and Asthma Proceedings. 30(3). 270–276. 11 indexed citations
3.
Day, James H., et al.. (2006). Experimental models for the evaluation of treatment of allergic rhinitis. Annals of Allergy Asthma & Immunology. 96(2). 263–278. 34 indexed citations
4.
Day, James H., et al.. (2005). A Note on Water. Allergy and Asthma Proceedings. 26(4). 275–82. 21 indexed citations
5.
6.
Day, James H., Maureen P. Briscoe, Elizabeth Rafeiro, et al.. (2004). Randomized double-blind comparison of cetirizine and fexofenadine after pollen challenge in the Environmental Exposure Unit: duration of effect in subjects with seasonal allergic rhinitis.. PubMed. 25(1). 59–68. 27 indexed citations
7.
Wilken, Jeffrey, Robert L Kane, Anne K. Ellis, et al.. (2003). A comparison of the effect of diphenhydramine and desloratadine on vigilance and cognitive function during treatment of ragweed-induced allergic rhinitis. Annals of Allergy Asthma & Immunology. 91(4). 375–385. 43 indexed citations
8.
Day, James H., Maureen P. Briscoe, Elizabeth Rafeiro, Douglass Chapman, & Benjamin Krämer. (2001). Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system. Annals of Allergy Asthma & Immunology. 87(6). 474–481. 47 indexed citations
9.
Day, James H., Maureen P. Briscoe, Elizabeth Rafeiro, et al.. (2000). Onset of action of intranasal budesonide (Rhinocort Aqua) in seasonal allergic rhinitis studied in a controlled exposure model. Journal of Allergy and Clinical Immunology. 105(3). 489–494. 56 indexed citations
10.
Day, James H. & Maureen P. Briscoe. (1999). Environmental exposure unit: a system to test anti-allergic treatment. Annals of Allergy Asthma & Immunology. 83(2). 83–93. 46 indexed citations
11.
Day, James H., Maureen P. Briscoe, & Michael D. Widlitz. (1998). Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: Effects after controlled ragweed pollen challenge in an environmental exposure unit. Journal of Allergy and Clinical Immunology. 101(5). 638–645. 92 indexed citations
12.
Small, Peter, Pierre-Alain Houle, James H. Day, et al.. (1997). A comparison of triamcinolone acetonide nasal aerosol spray and fluticasone propionate aqueous solution spray in the treatment of spring allergic rhinitis. Journal of Allergy and Clinical Immunology. 100(5). 592–595. 27 indexed citations
13.
Day, James H., et al.. (1997). Onset of Action, Efficacy, and Safety of a Single Dose of Fexofenadine Hydrochloride for Ragweed Allergy Using an Environmental Exposure Unit. Annals of Allergy Asthma & Immunology. 79(6). 533–540. 68 indexed citations
14.
Day, James H., et al.. (1997). Onset of Action and Efficacy of Terfenadine, Astemizole, Cetirizine, and Loratadine for the Relief of Symptoms of Allergic Rhinitis. Annals of Allergy Asthma & Immunology. 79(2). 163–172. 63 indexed citations
15.
Buckeridge, David L., et al.. (1996). Efficacy of Immunotherapy to Ragweed Antigen Tested by Controlled Antigen Exposure. Annals of Allergy Asthma & Immunology. 77(1). 74–80. 45 indexed citations
16.
Dolovich, Jerry, Maureen P. Briscoe, James Day, et al.. (1996). Intranasal fluticasone propionate versus loratadine in the treatment of adolescent patients with seasonal allergic rhinitis. Journal of Allergy and Clinical Immunology. 97(2). 588–595. 45 indexed citations
17.
18.
Small, Peter, Pierre-Alain Houle, James Day, et al.. (1996). 1003 Triamcinolone acetonide nasal spray (T) vs fluticasone propionate aqueous nasal spray (F) in patients with seasonal allergic rhinitis. Journal of Allergy and Clinical Immunology. 97(1). 433–433. 3 indexed citations
19.
Day, James, et al.. (1991). 54 Mass provocation for entry into a study establishing efficacy and tolerability of budesonide powder (turbohaler) in children with seasonal allergic rhinitis. Journal of Allergy and Clinical Immunology. 87(1). 152–152. 2 indexed citations
20.
Day, James H., et al.. (1990). Efficacy and safety of intranasal budesonide in the treatment of perennial rhinitis in adults and children.. PubMed. 64(5). 445–50. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by B. Hauswald Breakdown of academic impact, for papers by Markku Simola Breakdown of academic impact, for papers by Bo Sundin Breakdown of academic impact, for papers by L Businco Breakdown of academic impact, for papers by Mariana Couto Breakdown of academic impact, for papers by Max Jessen Breakdown of academic impact, for papers by Murat Kar Breakdown of academic impact, for papers by Anat Galor Breakdown of academic impact, for papers by J. M. Henriksen Breakdown of academic impact, for papers by Silvia Centellas
Rankless by CCL
2026